Early Combination Therapy in the Treatment of Type 2 Diabetes
This CME initiative was designed for nurse practitioners, physician assistants, and primary care providers working in diabetes care.
- Review current guideline recommendations for the initiation and intensification of therapy in patient with type 2 diabetes
- Discuss the benefits and risks of various classes of antihyperglycemic agents
- Discuss clinical considerations for early combination therapy
- Implement strategies to reduce clinical inertia in the treatment of patients with type 2 diabetes
Activity Launch Date - 12/4/18
Expiration Date - 12/4/19
Supporter Acknowledgment Statement
This activity is supported by an independent educational grant from Merck.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Statement of Independence
Horizon CME educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of Horizon CME to develop and present educational activities that are timely, fair balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome comments about how to better serve your needs.
Copyright© 2018 by Horizon CME. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from Horizon CME.
Vivian Fonseca, MD, FRCP
Professor of Medicine and Pharmacology
Tullis Tulane Alumni Chair in Diabetes
Chief, Section of Endocrinology
Tulane University Health Sciences Center
New Orleans, LA
Vivian A. Fonseca, MD, FRCP, is Professor of Medicine, the Tullis–Tulane Alumni Chair in Diabetes, and chief of the Section of Endocrinology at Tulane University Medical Center in New Orleans, Louisiana. He currently serves on the Board of Directors of the American Association of Clinical Endocrinologists (AACE), and the Board of Trustees of the American College of Endocrinology. He is a Past President for Science and Medicine of the American Diabetes Association (2012), and has held a leadership role and served on various committees in several other organizations including the American Diabetes Association, the American College of Endocrinology and the American Board of Internal Medicine.
Dr. Fonseca has served as a Consultant and given lectures for Takeda, Novo Nordisk, Sanofi- Aventis, Eli Lilly, Astra- Zeneca, Intarcia, Asahi. Tulane University has received Research Grants from Bayer and Boehringer Ingelheim.
Curtis Triplitt, PharmD, CDE
Texas Diabetes Institute
University Health System
Associate Professor of Medicine
Clinical /Div. of Diabetes
University of Texas Health Science Center at San Antonio
San Antonio, TX
Disclosures: Dr. Triplitt has served on a Speakers Bureau for AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, and Janssen Pharmaceuticals.
Felice Caldarella, MD, FACE, FACP, CDE
Endocrinologist Center for Endocrine Health
Hunterdon Medical Center
Disclosures: Dr. Caldarella discloses no relevant financial relationships with an ACCME-defined commercial interest in the last 12 months.
Planning Committee & Non-faculty Contributors
Additional non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose in the last 12 months.
Horizon CME requires instructors, planners, managers and other individuals who are in a position to influence the content of this activity to disclose any real or apparent conflict of interest (COI) which may arise as a result of prospective faculty members' relevant relationships with drug or device manufacturer(s). Horizon CME is committed to resolving all conflicts of interest and retaining only those speakers with financial interest conflicts that can be reconciled with the goals and educational integrity of the CME activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the providership of Horizon CME. Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.
Horizon CME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
How To Claim Credit
- Read the learning objectives and faculty disclosures
- Complete the Pre-test
- Participate in the activity
- Complete the Post-test and answer at least 2/3 questions correctly
- Complete Final Evaluation